// App-Quantinova.ai

[OP0062] : THE ADDITION OF ONE OR MORE BIOLOGICS TO METHOTREXATE IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS INCREASES THE INCIDENCE OF INFECTIONS AND SERIOUS ADVERSE EVENTS. THE 5882 PHARMACHILD COHORT

Researchers

Presenter

  • J. Swart

Principal Investigators

  • F. Bovis

  • C. Ailioaie

  • P. Quartier

  • F. De Benedetti

  • E. Tsitsami

  • B. Flato

  • P. Dolezalova

  • T. Constantin

  • T. Herlin

  • S. Kamphuis

  • S. Sawhney

  • E. Alekseeva

  • D. Maritsi

  • V. Vargova

  • L. Villa

  • C. Pallotti

  • A. Ravelli

  • A. Martini

  • N. Wulffraat

  • N. Ruperto

  • M. Hofer

  • S. Nielsen

  • J. Anton

  • A. Consolaro

  • V. Panaviene

  • V. Stanevicha

  • M. Trachana

Medical Centers

  • Wilhelmina Kinderziekenhuis, Utrecht, Netherlands

  • Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy

Locations

  • Italy

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Rheumatoid arthritis

  • Acute lymphoblastic leukemia

  • Thyroid Cancer

  • Shingles

  • Inflammatory Arthritis

  • Solid malignancies

  • Posterior Reversible Encephalopathy Syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Tocilizumab

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved